News Sentiment

GYRE sentiment intelligence

Gyre Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.05 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-7.2% over one week, -3.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Gyre Therapeutics Appoints Three New Members to its Board of Directors

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -7.2% Price reacting lower
Trend fit Trend inactive -3.2% over four weeks
Fair value -43.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 32
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 7
TradingView 4
GlobeNewswire 4
www.marketscreener.com 3
Investing.com Nigeria 2
marketscreener.com 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 15
Deals and strategy 4
Regulatory and legal 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
The Manila Times Direct company coverage

Gyre Therapeutics Appoints Three New Members to its Board of Directors

Gyre Therapeutics has appointed Yue Xiong, Ph.D., Maxwell Kirkby, and Claire Weston, Ph.D., to its Board of Directors, effective August 1, 2026. These appointments aim to enhance the company's expertise in scientific, clinical development, and cross-border biopharmaceutical opera

Tone
Positive 73/100
Event
Market update
Published
17 Jul 2026 06:39
Source
The Manila Times
Investing.com Direct company coverage

Gyre Therapeutics appoints three directors to board

Gyre Therapeutics announced the appointment of three new directors to its Board, effective August 1, 2026: Dr. Yue Xiong as Chief Scientific Officer, Maxwell Kirkby, and Dr. Claire Weston. This follows recent significant activities for the company, including the acquisition of Cu

Tone
Positive 63/100
Event
Deals and strategy
Published
16 Jul 2026 19:10
Source
Investing.com
Stock Titan Direct company coverage

Gyre Therapeutics (Nasdaq: GYRE) adds three directors, expanding expertise

Gyre Therapeutics announced the appointment of three new directors to its board, effective August 1, 2026: Dr. Yue Xiong, Maxwell Kirkby, and Dr. Claire Weston. These additions aim to expand the company's expertise in scientific, clinical development, and cross-border biopharmace

Tone
Positive 64/100
Event
Market update
Published
16 Jul 2026 18:10
Source
Stock Titan
Stock Titan Direct company coverage

Gyre Adds Director With Drug Development Experience Across China, Japan

Gyre Therapeutics has appointed three new directors to its Board, effective August 1, 2026: Yue Xiong, Maxwell Kirkby, and Claire Weston. These appointments aim to bolster the company's scientific, clinical development, governance, and cross-border biopharmaceutical expertise as

Tone
Positive 75/100
Event
Market update
Published
16 Jul 2026 18:10
Source
Stock Titan
Quartr Direct company coverage

Gyre Therapeutics (GYRE) Registration filing Summary

Gyre Therapeutics (GYRE) has filed a registration summary, detailing its focus as a commercial-stage biopharmaceutical company specializing in small-molecule therapies for organ fibrosis and inflammatory diseases. The company recently merged with Cullgen, expanding its therapeuti

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 02:43
Source
Quartr
Investing.com Australia Direct company coverage

Form S-3/A Gyre Therapeutics Inc For: 13 July By Investing.com

This article announces the filing of Form S-3/A by Gyre Therapeutics Inc for July 13. It is a brief report from Investing.com, providing financial news regarding the company. The article also lists various market data and other news headlines.

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 17:43
Source
Investing.com Australia
Stock Titan Direct company coverage

Gyre Therapeutics (Nasdaq: GYRE) details 31.3M-share resale and China risks

Gyre Therapeutics has filed an amended S-3 registration statement to allow for the resale of up to 31.3 million shares by existing stockholders, an increase from its original registration. The company highlighted significant legal and regulatory risks associated with its operatio

Tone
Neutral 50/100
Event
Regulatory and legal
Published
13 Jul 2026 21:11
Source
Stock Titan
AD HOC NEWS Direct company coverage

Gyre Therapeutics highlights pipeline progress as investors watch fibrosis focus

Gyre Therapeutics is gaining investor attention due to its specialization in therapies for fibrotic and inflammatory diseases, which address significant unmet medical needs. The company's core strategy is to develop drug candidates targeting key pathways in fibrosis, aiming to sl

Tone
Positive 75/100
Event
Market update
Published
07 Jul 2026 19:48
Source
AD HOC NEWS
Stock Titan Direct company coverage

If You Invested $1,000 in Gyre Therapeutics Inc (GYRE)

This article analyzes the historical performance of a $1,000 investment in Gyre Therapeutics Inc (GYRE) over various periods, showing significant negative returns. It also provides an overview of Gyre Therapeutics, a biopharmaceutical company focused on fibrosis-first therapies,

Tone
Negative 40/100
Event
Market update
Published
04 Jul 2026 06:09
Source
Stock Titan
Finviz Direct company coverage

GYRE - Gyre Therapeutics Inc Options

This article provides a detailed financial overview of Gyre Therapeutics Inc (GYRE), including its last closing price, dollar and percentage change, and various financial metrics such as market cap, income, sales, and employee count. It also lists key financial ratios like P/E, P

Tone
Positive 60/100
Event
Market update
Published
03 Jul 2026 07:40
Source
Finviz
Stock Titan Direct company coverage

GYRE SEC Filings - Gyre Therapeutics Inc 10-K, 10-Q, 8-K Forms

This page provides a comprehensive overview of Gyre Therapeutics (GYRE) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It details recent insider stock option grants to multiple directors and a COO's share transactions, alon

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 13:13
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Gyre Therapeutics Inc For: 30 June By Investing.com

This article from Investing.com announces the Form 4 filing for Gyre Therapeutics Inc., reflecting transactions made through June 30. The content primarily consists of market data, including indices, commodities, bonds, and shares, along with trending stocks and a series of other

Tone
Negative 41/100
Event
Market update
Published
01 Jul 2026 13:13
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Gyre Therapeutics (NASDAQ: GYRE) director awarded 40,000 stock options at $5.95

Gyre Therapeutics director Renate Parry was granted 40,000 stock options with an exercise price of $5.95 per share, expiring on June 10, 2036. The options will vest in 12 equal monthly installments through June 10, 2027, contingent on her continued service. This award is compensa

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 22:39
Source
Stock Titan
Stock Titan Direct company coverage

Gyre Therapeutics (GYRE) director awarded 40,000 stock options at $5.95

Gyre Therapeutics (GYRE) director Zhang Ping was granted 40,000 stock options with an exercise price of $5.95 per share. These options are set to expire on June 10, 2036, and will vest in 12 equal monthly installments through June 10, 2027, provided service continues. This transa

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 22:39
Source
Stock Titan
Stock Titan Direct company coverage

Director Rodney Nussbaum awarded 40,000 Gyre Therapeutics (GYRE) stock options

Gyre Therapeutics director Rodney L. Nussbaum was granted 40,000 stock options with an exercise price of $5.95 per share, expiring on June 10, 2036. This compensation-related award will vest in 12 equal monthly installments through June 10, 2027, provided his continued service to

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 22:39
Source
Stock Titan
Simply Wall Street Direct company coverage

US High Growth Tech Stocks to Watch

This article highlights top-performing high-growth tech stocks in the U.S., emphasizing strong innovation and adaptability. It reviews companies like Gyre Therapeutics, Neurocrine Biosciences, and Procore Technologies, detailing their recent developments, revenue growth, and mark

Tone
Positive 66/100
Event
Earnings
Published
30 Jun 2026 17:39
Source
Simply Wall Street
marketscreener.com Direct company coverage

Gyre Therapeutics, Inc.(NasdaqCM:GYRE) added to Russell Small Cap Comp Value Benchmark

Gyre Therapeutics, Inc. (NasdaqCM:GYRE) has been added to the Russell Small Cap Comp Value Benchmark. This inclusion follows several recent additions to various Russell indices, including the Russell 2000 Value, Russell 2000 Value-Defensive, Russell 2000 Growth-Defensive, Russell

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 12:40
Source
marketscreener.com
marketscreener.com Direct company coverage

Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value Benchmark

Gyre Therapeutics, Inc. (NasdaqCM: GYRE) has been added to the Russell 2000 Value Benchmark, according to a report published on June 29, 2026, by S&P Capital IQ. The biopharmaceutical company is focused on developing and commercializing therapies for liver fibrosis and other cond

Tone
Positive 91/100
Event
Market update
Published
29 Jun 2026 12:00
Source
marketscreener.com
ACCESS Newswire Direct company coverage

GYRE THERAPEUTICS (GYRE): Kaskela Law LLC Announces Shareholder Investigation of Gyre Therapeutics and Encourages Long-Term GYRE Investors to Contact the Firm

Kaskela Law LLC has initiated a shareholder investigation into Gyre Therapeutics, Inc. (NASDAQ: GYRE) to determine if the company's officers and directors violated securities laws or breached fiduciary duties. The firm encourages long-term Gyre shareholders to contact them to lea

Tone
Negative 28/100
Event
Regulatory and legal
Published
29 Jun 2026 06:00
Source
ACCESS Newswire
www.marketscreener.com Direct company coverage

Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Growth-Defensive Index

Gyre Therapeutics, Inc. (NasdaqCM: GYRE) has been added to the Russell 2000 Growth-Defensive Index. This inclusion comes alongside news of the company's F351 (hydronidone) drug for liver fibrosis advancing through regulatory processes in China, with an NMPA acceptance for a new d

Tone
Positive 76/100
Event
Regulatory and legal
Published
29 Jun 2026 02:41
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value-Defensive Index

Gyre Therapeutics, Inc. (NasdaqCM: GYRE) has been added to the Russell 2000 Value-Defensive Index. The biopharmaceutical company is focused on developing and commercializing F351 for MASH-associated fibrosis and expanding its pipeline in the PRC through Gyre Pharmaceuticals. Rece

Tone
Positive 69/100
Event
Market update
Published
29 Jun 2026 02:41
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 3000E Value Benchmark

Gyre Therapeutics, Inc. (NasdaqCM: GYRE) has been added to the Russell 3000E Value Benchmark. This inclusion follows several other recent additions to various Russell indices, including the Russell 2000 Value Benchmark, Russell 2000 Value-Defensive Index, and Russell 3000 Value B

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 01:08
Source
www.marketscreener.com
TradingView Direct company coverage

Price to earnings forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE

This page provides financial information for Gyre Therapeutics, Inc. (NASDAQ: GYRE), specifically its price to earnings forward. It is part of TradingView's market data offerings and includes various disclaimers regarding data sources.

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 03:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Gyre Therapeutics Inc – LS:A3EE5F

This article provides financial data for Gyre Therapeutics Inc (LS:A3EE5F), specifically its forward price-to-earnings ratio. It is presented in a data-centric format from TradingView, offering an overview of the company's financial metrics. The content highlights the period, val

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 21:38
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE

This article focuses on the enterprise value to revenue forward metric for Gyre Therapeutics, Inc. (NASDAQ: GYRE). It indicates that the company's financial data is available for analysis on TradingView, which provides market, financial, and other relevant information for the pha

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:10
Source
TradingView
TradingView Direct company coverage

Gyre Therapeutics Inc Actuals & Estimates (NASDAQ:GYRE)

This article provides an overview of Gyre Therapeutics, Inc. (NASDAQ:GYRE) stock, including its current price, performance, analyst forecasts, and financial data. It covers historical price movements, volatility, market capitalization, and upcoming earnings reports, offering a co

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 01:10
Source
TradingView